National lupus organizations, and individuals with lupus and their families around the world, are rallying to protect access to new treatments of lupus.
European Review Board Issues Positive Opinion for Benlysta®
May 20, 2011
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (HGSI) have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending marketing authorisation for BENLYSTA® (belimumab) as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus, with a high degree of disease activity (e.g. positive anti-dsDNA and low complement), despite standard therapy. Read the entire release published on the HGSI website
Health Canada and European Regulators have approved BENLYSTA™.